1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33-39.
2. Mizuno Y, Mori H, Kondo T. Parkinson's disease: from etiology to treatment. Intern Med 1995; 34:1045-1054.
3. Kopin IJ. Tips from toxins: the MPTP model of Parkinson's disease. In: Jolles G, Stutzman JM, eds. Neurodegenerative Diseases. San Diego: Academic Press Limited, 1994:143-154.
4. Golbe LI. Alpha-synuclein and Parkinson's disease. Mov Disord 1999; 14:6-9.
5. Wszolek ZK, Uitti RJ, Markopoulou K. Familial Parkinson's disease and related conditions: clinical genetics. Adv Neurol 2001; 86:33-43.
6. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51:296-301.
7. Payami H, Zareparsi S. Genetic epidemiology of Parkinson's disease. J Geriatr Psychiatry Neurol 1998; 11:98-106.
8. Brooks DJ. Parkinson's disease: a single clinical entity? QJM 1995; 88:81-91.
9. Calne DB. Parkinson's disease is not one disease. Parkinsonism Relat Disord 2000; 7:3-7.
10. Uitti RJ, Calne DB, Dickson DW, Wszolek ZK. Is the neuropathological "gold standard" diagnosis dead? Implications of clinicopathologic findings in an autosomal dominant neurodegenerative disorder. Parkinsonism Relat Disord 2004; 10:461-463.
11. Lazzarini AM, Myers RH, Zimmerman TR Jr, et al. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 1994; 44:499-506.
12. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996; 47:155-160.
13. Rocca WA, McDonnell SK, Strain KJ, et al. Familial aggregation of Parkinson's disease: the Mayo Clinic family study. Ann Neurol 2004; 56:495-502.
14. De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord 1996; 11:17-23.
15. Uitti RJ, Shinotoh H, Hayward M, Schulzer M, Mak E, Calne DB. "Familial Parkinson's disease": a case-control study of families. Can J Neurol Sci 1997; 24:127-132.
16. Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000; 343:1765-1770.
17. Maher NE, Golbe LI, Lazzarini AM, et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology 2002; 58:79-84. Erratum in: Neurology 2002; 58:1136.
18. Simon DK, Lin MT, Pascual-Leone A. "Nature versus nuture" and incompletely penetrant mutations. J Neurol Neurosurg Psychiatry 2002; 72:686-689.
19. Duvoisin RC, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. Neurology 1981; 31:77-80.
20. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33:815-824.
21. Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson's disease: a reappraisal. Mov Disord 1990; 5:187-194.
22. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. J Am Med Assoc 1999; 281:341-346.
23. Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 2004; 63:305-311.
24. Dickson D, Farrer M, Lincoln S, et al. Pathology of PD in monozygotic twins with a 20-year discordance interval. Neurology 2001; 56:981-982.
25. Laihainen A, Ruottinen H, Rinne JO, et al. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol 2000; 247(suppl 2):II110-II113.
26. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45:577-582.
27. Gowers WR. A Manual of Diseases of the Nervous System. Philadelphia: P Blakiston, Son & Co, 1888.
28. Bell J, Clark AJ. A pedigree of paralysis agitans. Ann Eugenics 1925-1926; i:455-462.
29. Allen W. Inheritance of the shaking palsy. Arch Intern Med 1937; 60:424-436.
30. Mjönes H. Paralysis agitans: a clinical and genetic study. Acta Psychiat Neurol Scand 1949; 54(suppl):1-195.
31. Wszolek ZK, Markopoulou K, Chase BA. Genetics of Parkinson's disease and parkin-sonian disorders. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles & Practice. 2nd ed. New York: McGraw-Hill, 2004:163-176.
32. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27:276-282.
33. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998; 18:262-265.
34. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
35. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neu-rol Scand 1994; 89:347-352.
36. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-608.
37. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395:451-452.
38. van Duijn CM, Dekker MC, Bonifati V, et al. PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001 Sep; 69:629-634.
39. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004 May 21; 304:1158-1160.
40. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARKS-linked Parkinson's disease. Neuron 2004; 44:595-600.
41. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44:601-607.
42. Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ. LRRK2 mutations and Parkinsonism. Lancet 2005; 365:1229-1230.
43. Nichols WC, Pankratz N, Hernandez D, et al, Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familiar Parkinson's disease. Lancet 2005; 365:410-2.
44. Di Fonzo A, Rohe CF, Ferreira J, et al, Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365:412-5.
45. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365:415-416.
46. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005 Apr; 76:672-680.
47. Hernandez D, Paisan Ruiz C, Crawley A, et al. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 2005; 389:137-139.
48. Infante J, Rodriguez E, Combarros O, et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett 2006; 395:224-226.
49. Goldwurm S, Di Fonzo A, Simons EJ, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005; 42:e65.
50. Bialecka M, Hui S, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease. Neurosci Lett 2005; 390:1-3.
51. Lesage S, Ibanez P, Lohmann E, et al. French Parkinson's Disease Genetics Study Group. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58:784-787.
52. Bras JM, Guerreiro RJ, Ribeiro MH, et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portugese cohort. Mov Disord 2005; 20:1653-1655.
53. Lesage S, Dürr A, Tazir M, et al. LRRK2 G2019S as a Cause of Parkinson's Diesease in North African Arabs. N Engl J Med 2006; 354:422-423.
54. Saigoh K, Wang YL, Suh JG, et al. Intragenic deletion of the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23:47-51.
55. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287:1265-1269.
56. Kahle PJ, Neumann M, Ozmen L, et al. Selective insolubility of a-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001; 159:2215-2225.
57. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-ß attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-177.
58. Farrer M, Maraganore DM, Lockhart P, et al. a-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001; 10:1847-1851.
59. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999; 45:611-617.
60. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999; 53:1858-1860.
61. Zhang J, Hattori N, Leroy E, et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord 2000; 6:195-197.
62. Satoh J, Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiq-uitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci 2001; 189:113-117.
63. Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003; 54:271-274.
64. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 2003; 54:283-286.
65. Hedrich K, Djarmati A, Schafer N, et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 2004; 62:389-394.
66. Sinha R, Racette B, Perlmutter JS, Parsian A. Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2005; 11:341-347.
67. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56:336-341.
68. Lesage S, Durr A, Tazir M, et al. French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006; 354:422-423.
69. Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005; 57:933-934.
70. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001 Apr; 68:895-900.
71. Valente EM, Brancati F, Ferraris A, et al. European Consortium on Genetic Susceptibility in Parkinson's Disease. PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002; 51:14-18.
72. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002; 52:549-555.
Was this article helpful?